445041-29-2 Usage
Uses
Used in Pharmaceutical and Agrochemical Industries:
2,5-Dichloro-quinazoline is used as a chemical intermediate for the synthesis of various pharmaceuticals and agrochemicals, leveraging its versatile reactivity to form a range of derivatives that contribute to the development of new drugs and pesticides.
Used in Dye and Pigment Production:
In the dye and pigment industry, 2,5-Dichloro-quinazoline is utilized as a key component in the production of dyes and pigments, capitalizing on its chemical properties to create a variety of colorants for different applications.
Used in Antitumor Research:
2,5-Dichloro-quinazoline is used as a potential antitumor agent in the field of oncology research, where its pharmacological properties are being explored for their ability to combat cancer cells, with ongoing studies to understand its full potential and safety profile.
Check Digit Verification of cas no
The CAS Registry Mumber 445041-29-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,4,5,0,4 and 1 respectively; the second part has 2 digits, 2 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 445041-29:
(8*4)+(7*4)+(6*5)+(5*0)+(4*4)+(3*1)+(2*2)+(1*9)=122
122 % 10 = 2
So 445041-29-2 is a valid CAS Registry Number.
445041-29-2Relevant academic research and scientific papers
IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS
-
Paragraph 0747, (2019/10/17)
The present disclosure relates to heterocyclic compounds and methods which may be useful as inhibitors of transcription activating proteins such as CBP and P300 for the treatment or prevention of diseases such as proliferative diseases, inflammatory disorders, autoimmune diseases, and fibrotic diseases.
NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS
-
Page/Page column 185, (2011/12/02)
Unsaturated nitrogen heterocyclic compounds of formula (I): (I), as defined in the specification, compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, Huntington's Disease, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.
2 -ARYLAMINOQUINAZOLINES FOR TREATING PROLIFERATIVE DISEASES
-
Page/Page column 191-192, (2010/01/12)
The invention provides novel compounds that are inhibitors of PDKI. Also provided are pharmaceutical compositions including the compounds, and methods of treating proliferative diseases, such as cancers, with the compounds or composition.
